SpyGlass Pharma (SGP) Citigroup’s Biopharma Back to School Summit 2026 summary

Technology overview and clinical development

• Lead asset is a drug-eluting intraocular lens (IOL) delivering bimatoprost for up to three years, addressing both cataract and glaucoma in a single procedure.

• The IOL uses a proprietary design with non-bio-erodible drug pads, ensuring uncompromised vision quality and consistent drug delivery.

• Clinical data from first-in-human and phase I/II studies show up to 95% of patients medication-free at three years and a 34–37% mean IOP reduction.

• Phase III trials are underway with 800 patients across 90+ sites, focusing on efficacy, safety, and visual acuity endpoints.

• Four-year data from the first-in-human study and first-in-human trial for a next-generation drug ring system (BIM-DRS) are expected by year-end.

Market opportunity and competitive positioning

• Approximately 1 million annual U.S. cataract procedures involve patients with glaucoma, representing a significant addressable market.

• The solution streamlines workflow for all cataract surgeons, potentially unlocking half the market currently not using minimally invasive glaucoma procedures.

• The product is positioned as a time-saving, single-procedure alternative to separate lens replacement and glaucoma interventions.

• Reference products (iDose, DURYSTA) set a three-year drug delivery price floor at $14,000, guiding future pricing strategy.

Reimbursement, economics, and manufacturing

• A new Category III CPT code was granted, providing additional professional fees for surgeons without increasing facility costs.

• Drug reimbursement will follow ASP +6% model, benefiting ambulatory surgery centers.

• Manufacturing is U.S.-based, with process development in-house and scalable through contract manufacturers.